Gilead’s Biktarvy reinforced as a treatment option for HIV
HIV affects approximately 39 million people worldwide and can lead to AIDS
Read Moreby Jen Brogan | Oct 19, 2023 | News | 0
HIV affects approximately 39 million people worldwide and can lead to AIDS
Read Moreby Lucy Parsons | Mar 8, 2021 | News | 0
Data from two Phase III studies demonstrated durable viral suppression in HIV-1 patients
Read Moreby Selina McKee | Sep 11, 2018 | News | 0
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.
Read Moreby Selina McKee | Apr 30, 2018 | News | 0
Three medicines treating HIV, pain and cancer have been recommended for approval by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) at its latest meeting.
Read Moreby Selina McKee | Feb 8, 2018 | News | 0
Gilead’s new combination therapy Biktarvy has been approved by the US Food and Drug Administration for the treatment of HIV.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
